CHATSWORTH, CA / ACCESSWIRE / February 6, 2017 / Cavitation Technologies, Inc. (OTCQB: CVAT; Berlin: WTC), is pleased to announce that it has entered into a consulting agreement with PharmaConsult Ltd. The agreement calls for PharmaConsult Ltd. to advise Cavitation Technologies, Inc. on the strategic expansion of its patented NANOreactor® technology into the pharmaceutical industry in order to improve the delivery of active pharmaceutical ingredients by creating a nano-sized droplets that allow significant absorption rate due to sub-micron particle size. CVAT technology offers ecologically friendly, greener processing technique for the generation of pharmaceutical grade nano emulsions, which improves thermodynamic stability, bioavailability, increased drug solubilization and rapid dissolution after administration.
Roman Gordon, Global Technology Manager, commented, "We see PharmaConsult Ltd. as a valuable partner for Cavitation Technologies, Inc. to help us enter the field in the pharmaceutical industry. We look forward to working with PharmaConsult Ltd. to accelerate the development of new drug delivery methods and enhance our portfolio of products."
"We are pleased that Cavitation Technologies, Inc. has selected us as their partner. Many drugs currently fail the clinical trial phase due to poor bioavailability and our knowledge in the pharmaceutical industry will allow us to give CVAT the necessary support to help the Company to present their unique patented technology to the pharmaceutical industry," says Dana Rubin, founder of PharmaConsult Ltd.
Cavitation Technologies, Inc. develops high-efficiency technologies for processing fluids in various industries and is uniquely positioned to provide their technology to pharmaceutical and medical cannabis industry.
About CTi:
Founded in 2007, the company designs and manufactures state-of-the-art, flow-through, devices and systems as well as develops processing technologies for use in edible oil refining, renewable fuel production, expeditious petroleum upgrading, algae oil extraction, alcoholic beverage enhancement and water treatment. As an add-on to its existing neutralization systems, the company's patented Nano Reactor ® allows refiners to significantly reduce both processing costs and environmental impact, while also increasing yield.
About PharmaConsult Ltd.
PharmaConsult Ltd. is an independent consulting company which advises mid-sized and start-up pharmaceutical and biotechnology companies. PharmaConsult specializes in guiding startups specifically cannabinoid based therapeutics with regulatory guidance, compliance, and information for the FDA, DEA and other regulatory agencies. PharmaConsult specializes in providing tools that help companies develop a strategic plan to gain a sustainable competitive advantage. They offer support for Generics, Branded Drugs, Biosimilars and Cannabinoid Therapeutics.
http://www.pharmaconsultltd.com/
Forward Looking Statement:
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements regarding the anticipated installation and the timing of the installation, our intent to continue to focus on research and development, marketing and sales of our unique technology, our belief that our company is positioned for accelerated growth and the expected efforts to be made to enhance our shareholder's value. These forward-looking statements are based largely on the Company's expectations and are subject to a number of risks and uncertainties, certain of which are beyond the Company's control. Actual results could differ materially from these forward looking statements as a result of a variety of factors including, among others, the state of the economy, the competitive environment and our ability to perform the installation as anticipated and other factors described in our most recent Form 10-K and our other filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. In light of these risks and uncertainties there can be no assurances that the forward looking statements contained in this press release will in fact transpire or prove to be accurate. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Contact:
Investor Relations
Jessica Steidinger
Jessica@ctinanotech.com
Phone (818) 718-0905
SOURCE: Cavitation Technologies, Inc.